V
70
2
RL
76
-3
FAST
64
-3
WHR
66
-7
VFC
59
-2
EIX
70
-2
VLO
40
-2
URI
70
-2
MKC
51
-3
OI
45
-5
LOW
56
-3
ACN
65
16
ED
46
-3
WBA
48
-5
HP
41
-4
STI
12
-2
CMI
62
-2
OMC
66
-2
UNH
65
-4
WMB
70
-2
V
70
2
RL
76
-3
FAST
64
-3
WHR
66
-7
VFC
59
-2
EIX
70
-2
VLO
40
-2
URI
70
-2
MKC
51
-3
OI
45
-5
LOW
56
-3
ACN
65
16
ED
46
-3
WBA
48
-5
HP
41
-4
STI
12
-2
CMI
62
-2
OMC
66
-2
UNH
65
-4
WMB
70
-2
Financhill
Back

Travere Therapeutics 10K Form

Sell
37

TVTX
Travere Therapeutics

Last Price:
18.5700
Seasonality Move:
13.52%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TVTX News And Ratings

See the #1 stock for the next 7 days that we like better than TVTX

TVTX Financial Statistics

Sales & Book Value

Annual Sales: $145.24M
Cash Flow: $-50.7M
Price / Cash Flow: 0
Annual Sales: $-0.39
Price / Book: 0

Profitability

EPS (TTM): -4.55000
Net Income (TTM): $-351.45M
Gross Margin: $133.79M
Return on Equity: -325.82%
Return on Assets: -52.6%

Travere Therapeutics Earnings Forecast

Key Travere Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for TVTX is 92.12%.
  • The Selling, General & Administrative Expenses for TVTX have been equal to 182.83% of Gross Profit Margin.
  • The Research & Development expenses have been 168.68% of Revenue.
  • The Interest Expense is -10.17% of Operating Income.
  • The Net Earning history of TVTX is -76.70% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 4 years.

Travere Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TVTX
CUSIP: 89422G
Website: travere.com

Debt

Debt-to-Equity Ratio: -12.43
Current Ratio: 1.71
Quick Ratio: 1.59

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TVTX Technical Analysis vs Fundamental Analysis

Sell
37
Travere Therapeutics (TVTX) is a Sell

Is Travere Therapeutics a Buy or a Sell?